Key result
Nesiritide reduces peak creatinine increase by ~56% vs placebo in LV dysfunction patients undergoing CABG.
Why the study?
Nesiritide might be useful in managing patients with left ventricular dysfunction undergoing cardiac surgery due to its hemodynamic, neurohormonal, and renal effects, but its role in this setting was unclear.
RCT (n=303)
double-blind
randomly assigned
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Patients on nesiritide had significantly greater urine output within 24 hours after surgery and overall better preservation of kidney functioning during hospitalization as well as two weeks after surgery.”
“These kidney, safety and mortality findings from the NAPA trial are encouraging as they suggest that nesiritide may provide important clinical benefit to heart failure patients undergoing CABG surgery with cardiopulmonary bypass. We are assessing the design of a Phase 3 trial in cardiac surgery patients to further study this investigational use of nesiritide and will be submitting these data to the F.D.A.”
Randomized trial reveals preserved renal function with perioperative nesiritide in patients undergoing cardiac surgery, indicating improved postoperative recovery.
OBJECTIVES: The purpose of this study was to determine the role nesiritide might play in patients with left ventricular dysfunction undergoing coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB). BACKGROUND: Given the hemodynamic, neurohormonal, and renal effects of natriuretic peptides, nesiritide might be useful in the management of patients undergoing cardiac surgery. METHODS: This prospective, double-blind, exploratory evaluation randomly assigned patients with ejection fraction </=40% who were undergoing CABG with anticipated use of CPB to receive either nesiritide or placebo, in addition to usual care, for 24 to 96 h after induction of anesthesia. Postoperative renal function, hemodynamics, and drug use (primary end points) were assessed in patients who underwent CABG using CPB; mortality and safety (secondary end points) were assessed in all patients who received the study drug. RESULTS: Of 303 randomized patients, 279 received the study drug and 272 underwent CABG using CPB. Compared with placebo, nesiritide was associated with a significantly attenuated peak increase in serum creatinine (0.15 +/- 0.29 mg/dl vs. 0.34 +/- 0.48 mg/dl; p < 0.001) and a smaller fall in glomerular filtration rate (-10.8 +/- 19.3 ml/min/1.73 m(2) vs. -17.2 +/- 21.9 ml/min/1.73 m(2); p = 0.001) during hospital stay or by study day 14, and a greater urine output (2,926 +/- 1,179 ml vs. 2,350 +/- 1,066 ml; p < 0.001) during the initial 24 h after surgery. In addition, nesiritide-treated patients had a shorter hospital stay (p = 0.043) and lower 180-day mortality (p = 0.046). CONCLUSIONS: Nesiritide in the setting of CABG with CPB is associated with improved postoperative renal function and possibly enhanced survival. (The NAPA Trial; ; ).
No takes yet. Share an insight, caveat, or question.
Mentzer et al. (2006) conducted an RCT in Left ventricular dysfunction undergoing coronary artery bypass grafting (CABG) (n=303). Nesiritide vs. Placebo was evaluated on Peak increase in serum creatinine (p=< 0.001). Nesiritide attenuated the peak increase in serum creatinine compared with placebo in patients with LV dysfunction undergoing CABG.
Synapse has enriched 10 related papers. Consider them for comparative context: